Ribavirin-Astrapharm

Direct-acting antivirals. Nucleosides and nucleotides, with the exception of reverse transcriptase inhibitors. Treatment of chronic hepatitis C (CHC) in combination with other drugs.

Contraindications.

• Hypersensitivity to ribavirin or to any of the excipients.
• Severe heart disease, including unstable and uncontrolled forms, observed within 6 months before treatment.
• Severe debilitating diseases.
• Chronic renal failure or creatinine clearance <50 ml / min and / or conditions requiring hemodialysis.
• Severe hepatic impairment (Child-Pugh classification B or C) or decompensated liver cirrhosis.
• Peginterferon alfa-2b is contraindicated in patients co-infected with hepatitis C / HIV, liver cirrhosis and hepatic impairment> 6 Child-Pugh scores.
• Presence of anamnestic or clinical evidence of a severe mental disorder, in particular major depression, suicidal ideation, or suicide attempt in children.
• Autoimmune hepatitis or other autoimmune diseases in the anamnesis (due to combination with interferon alfa-2b or interferon alfa-2b).
• Hemoglobinopathies (eg thalassemia, sickle cell anemia).
• Pregnancy. Ribavirin-Astrapharm treatment should only be started after receiving a negative pregnancy test immediately before starting treatment.
• Breastfeeding period.

The therapy should be carried out by a doctor with experience in the treatment of chronic hepatitis C. The drug Ribavirin-Astrafarm should be taken 2 times a day (morning and evening) with meals. Due to the teratogenic potential of Ribavirin capsules
should be broken.
Ribavirin should be used in combination with interferon alfa-2a or interferon alfa-2a. The exact dose and duration of the drug depends on the interferon used. For additional information on dosage and duration of use, see the instructions for use of peginterferon alfa-2a or interferon alfa-2a in the case of using Ribavirin in combination with one of these drugs.